LivaNova PLC (LIVN) Stock
Company insiders reported 0 open-market buys and 4 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
Are LivaNova PLC insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 10, 26 | Bianchi Francesco | Director | SELL | 3.5K | $273K |
| Sep 4, 26 | Story Brooke | Director | SELL | 2.3K | $187K |
| Aug 31, 26 | Bianchi Francesco | Director | SELL | 1.6K | $132K |
| Aug 11, 26 | Tezel Ahmet | Chief Innovation Officer | SELL | 2.7K | $208K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →LIVN price chart
Powered by TradingViewWhat does LivaNova PLC do?
LivaNova is a global medical technology company that develops innovative devices and therapies for cardiac surgery, cardiopulmonary support, and neuromodulation treatments. The company's primary product portfolio includes vagus nerve stimulation therapy for drug-resistant epilepsy and difficult-to-treat depression, along with advanced cardiopulmonary solutions for cardiac surgical procedures. LivaNova serves healthcare providers and patients worldwide, addressing critical medical needs in neurology and cardiovascular care. Established through the 2015 merger of Cyberonics and Sorin, the company combines decades of expertise in both neuromodulation and cardiopulmonary innovation. Operating through specialized business units headquartered in different regions, LivaNova also maintains a digital health initiative focused on epilepsy treatment support. The company is headquartered in London and employs thousands of professionals dedicated to transforming patient outcomes through advanced medical technology solutions.